[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correspondence
July 01, 2005

Prevention of Steroid-Induced Intraocular Pressure Elevation—Reply

Arch Ophthalmol. 2005;123(7):1020. doi:10.1001/archopht.123.7.1020-a

In reply

We thank Dr Kahana for his letter and comments regarding the article entitled, “Prevention of Corticosteroid-Induced Intraocular Pressure Elevation From ISV-205.”

The drug ISV-205 was developed with the proprietary delivery vehicle, DuraSite (InSite Vision Incorporated), to deliver sufficient concentrations of diclofenac (the active ingredient) into the anterior chamber to prevent the corticosteroid alteration of the trabecular meshwork. Prior research results of this formulation remain proprietary.

First Page Preview View Large
First page PDF preview
First page PDF preview
×